See more : ADLPartner SA (ALP.PA) Income Statement Analysis – Financial Results
Complete financial analysis of 908 Devices Inc. (MASS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 908 Devices Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) Income Statement Analysis – Financial Results
- CPT Technology (Group) Co.,Ltd (000536.SZ) Income Statement Analysis – Financial Results
- Grade Upon Technology Corp (6739.TWO) Income Statement Analysis – Financial Results
- Japan Tobacco Inc. (JAPAY) Income Statement Analysis – Financial Results
- Beite Energy Corporation (BTNY) Income Statement Analysis – Financial Results
908 Devices Inc. (MASS)
About 908 Devices Inc.
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 50.23M | 46.85M | 42.21M | 26.89M | 17.97M | 22.05M |
| Cost of Revenue | 24.91M | 20.83M | 18.97M | 11.97M | 9.83M | 9.66M |
| Gross Profit | 25.32M | 26.02M | 23.23M | 14.92M | 8.14M | 12.39M |
| Gross Profit Ratio | 50.41% | 55.54% | 55.05% | 55.49% | 45.31% | 56.19% |
| Research & Development | 21.90M | 17.53M | 13.07M | 8.24M | 8.99M | 9.53M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 46.18M | 43.88M | 32.24M | 12.50M | 11.29M | 9.30M |
| Other Expenses | 0.00 | 1.82M | 386.00K | -6.03M | 301.00K | 50.00K |
| Operating Expenses | 68.08M | 61.41M | 45.30M | 20.74M | 20.29M | 18.83M |
| Cost & Expenses | 92.99M | 82.23M | 64.28M | 32.71M | 30.12M | 28.49M |
| Interest Income | 6.48M | 2.03M | 500.00K | 100.00K | 200.00K | 0.00 |
| Interest Expense | 201.00K | 129.00K | 486.00K | 976.00K | 1.53M | 1.15M |
| Depreciation & Amortization | 2.38M | 1.61M | 925.00K | 831.00K | 900.00K | 896.00K |
| EBITDA | -34.03M | -31.82M | -20.94M | -11.01M | -10.94M | -5.49M |
| EBITDA Ratio | -67.74% | -75.52% | -51.37% | -44.04% | -60.89% | -24.91% |
| Operating Income | -42.76M | -35.38M | -22.07M | -5.82M | -12.14M | -6.44M |
| Operating Income Ratio | -85.13% | -75.52% | -52.29% | -21.62% | -67.57% | -29.20% |
| Total Other Income/Expenses | 6.15M | 1.82M | -100.00K | -7.00M | -1.23M | -1.10M |
| Income Before Tax | -36.61M | -33.56M | -22.17M | -12.82M | -13.37M | -7.54M |
| Income Before Tax Ratio | -72.89% | -71.64% | -52.53% | -47.66% | -74.41% | -34.17% |
| Income Tax Expense | -211.00K | -1.82M | -53.00K | -5.88M | 1.83M | 50.00K |
| Net Income | -36.40M | -31.74M | -22.12M | -6.94M | -15.20M | -7.54M |
| Net Income Ratio | -72.47% | -67.75% | -52.40% | -25.79% | -84.60% | -34.17% |
| EPS | -1.13 | -1.01 | -0.79 | -0.25 | -0.58 | -0.40 |
| EPS Diluted | -1.13 | -1.01 | -0.79 | -0.25 | -0.58 | -0.40 |
| Weighted Avg Shares Out | 32.21M | 31.49M | 27.96M | 27.27M | 26.20M | 18.98M |
| Weighted Avg Shares Out (Dil) | 32.24M | 31.49M | 27.96M | 27.27M | 26.20M | 18.98M |
908 Devices and Terumo Blood and Cell Technologies Collaborate to Add On-line Analytics to Quantum Flex Cell Expansion System
BOSTON & LAKEWOOD, Colo.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and medical technology company Terumo Blood and Cell Technologies (Terumo BCT) announce a collaboration to enable on-line monitoring...
908 Devices to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences. 53rd Annual Baird Industrial Conference In-person presentation only on Wednesday, November...
908 Devices Awarded $10.4M Order from the United States Air Force for its Handheld MX908 Device
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces today that it has been awarded a total of $10.4 million in purchase orders from the United States Air Force...
908 Devices to Report Third Quarter Financial Results on November 7, 2023
BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the third quarter 2023 before market open on Tuesday, November 7, 2023. Company management...
908 Devices Enters Initial Production Phase of US Department of Defense Aerosol and Vapor Chemical Agent Detector Program
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces that it has entered the initial production phase of the Aerosol and Vapor Chemical Agent Detector (AVCAD) program. The company...
908 Devices Launches MAVERICK for Real-Time In-Line Monitoring of Multiple Bioprocess Parameters
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the launch of MAVERICK, an optical in-line analyzer that provides real-time monitoring and control of glucose, lactate, and total biomass...
908 Devices to Participate in the Gilmartin Group Emerging Growth Company Showcase
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming Gilmartin Group Emerging Growth Company Showcase. 908 Devices' management is scheduled to present...
908 Devices: Not Worth Investing
908 Devices announced Q2 FY23 results with an 8.9% increase in revenue, driven by a 27% increase in MX908 device sales. The company experienced a significant drop in gross profit margin and an increase in operating expenses, resulting in a...
3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street
Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices.
5 Stocks Wall Street and ARK's Cathie Wood Love Are Trading Under $10 With Huge Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Source: https://incomestatements.info
Category: Stock Reports